This may contribute to explain the relationship between ZFP90 and PRKAB2. PRKAB2 is also one of the target genes of Fostamatinib that is a drug approved by the US Food and Drug Administration (FDA) in 2018 for the treatment of idiopathic thrombocytopenic purpura. Here, PRKAB2 is linked to autoimmune thrombocytopenic purpura.